Publications
J. Lee, B. Kim, H. -M. Woo, Kim, J. -W. Kim, I. Jung, S. -W. Park, Y. -S. Kim, J. -H. Na*, S. T. Jung*(2024) "Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs", Molecular pharmaceutics, 21(9), 4336–4346.
S. Krishna, S. T. Jung*, E. Y. Kim* (2024) “Escherichia coli and Pichia pastoris: microbial cell-factory platform for full-length IgG production”, Critical Reviews in Biotechnology, 1–23. Advance online publication.
S. M. Lee, S.-W. Min, H. S. Kwon, G.-D. Bae, J. H. Jung, H. I. Park, S. H. Lee, C. S. Lim, B. J. Ko, J. C. Lee*, S. T. Jung* (2023) “Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20”, Scientific Reports, 13, 18275.
W. Lee, S. M. Lee, S. T. Jung* (2023) “Unlocking the Power of Complement-Dependent Cytotoxicity: Antibody Engineering Strategies for Development of Potent Therapeutic Antibodies for Cancer Treatments”, BioDrugs, 37:5, 637-648
W. S. Kim, H. D. Chae, , I. Jung, W.-K. Lee, W. J. Lee, J. Lee, Y. Gong, D. Lee, B.-W. Kim, J.-K. Kim, J. Hwang, D.-H. Kweon, S. T. Jung*, J.-H. Na* (2023) “Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein”, Fish & Shellfish Immunology, 138, 108807.
J. Y. Ha, K.-J. Chun, S. Ko, H. W. Lee, O. K. Hwang, C. S. Lim, K. Ha, B. J. Ko, S. T. Jung* (2023) “Glycan-controlled human PD-1 variants displaying broad-spectrum high binding to PD-1 ligands potentiate T cell”, Molecular Pharmaceutics, 20(4), 2170-2180.
S. Ko, M.-S. Ju, H.-M. Ahn, J.-H. Na, W. H. Ko, M. Jo, M. Kyung, C. S. Lim, B. J. Ko,, W.-K. Lee, Y.-J. Kim, S. T. Jung* (2023) “Engineered human antibody with improved endothelin receptor type A binding affinity, developability, and serum persistence exhibits excellent antitumor potency”, Molecular Pharmaceutics, 20, 1247-1255.
W. S. Kim, J. H. Kim, J. Lee, S. Y. Ka, H. D. Chae, I. Jung, S. T. Jung*, J.-H. Na*, (2022) “Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of Escherichia coli”, Bioengineering, 9(11), 670.
S. Ko, Sora Park, Myung Ho Sohn, M. Jo, B. J. Ko, Jung-Hyun Na, Hojin Yoo, Ae Lee Jeong, Kyungsoo Ha, Ju Rang Woo, Chungsu Lim, Jung Hyu Shin, Dohyun Lee, So-Young Choi, S. T. Jung* (2022) "An Fc variant with two mutations confers prolonged serum half-lie and enhanced effector functions on IgG anbidodies", Experimental and Molecular Medicine, 1226-3613.
Minjong Lee, Byunghwa Kang, Juhwa Lee, Jisun Lee, S. T. Jung, Chang Yun Son, Seung Soo Oh (2022) "De novo selected hACE2 mimics that integrate hot-spot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants", Science Advances, 8(43), eabq6207, 2375-2548.
Hyo-Jung Lee, Kwon-Ho Song, Se Jin Oh, Suyeon Kim, Eunho Cho, Jungwon Kim, Yun gyu Park, Kyung-Mi Lee, Cassian Yee, Seung-Hwa Song, Suhwan Chang, Jungmin Choi, S. T. Jung, and Tae Woo Kim (2022) "Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes", Nature Communications, 13(1), 2127, 2041-1723.
P. Jebamani, D. K. Sriramulu, S. T. Jung, S.-G. Lee (2022) "Structural study on the impact of S239D/I332E mutations in the binding of Fc and FcγRIIIa", Biotechnology and Bioprocess Engineering, 26, 985-992, 1226-8372.
M.-S. Ju, H.-M. Ahn, S.-G. Han, S. Ko, J.-H. Na, M. Jo, C. S. Lim, B. J. Ko, Y. G. Yu, W.-K. Lee, Y.-J. Kim, S. T. Jung* (2021) “A human antibody against human endothelin receptor type A that exhibit anti-tumor potency”, Experimental and Molecular Medicine, 53, 1437-1448.
H. Zheng, J. Y. Lim, Y. Kim, S. T. Jung, S. W. Hwang (2021) “The role of oxytocin, vasopressin, and their receptors at nociceptors in peripheral pain modulation”, Frontiers in Neuroendocrinology, 63, 100942.
W. Lee, K. N. Bobba, J. Y. Kim, H. Park, A. Bhise, W. Kim, K. Lee, S. Rajkumar, B. Nam, K. C. Lee, S. H. Lee, S. Ko, H. J. Lee, S. T. Jung, J. Yoo (2021) “A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images”, Journal of Materials Chemistry B, 9:13, 2993-2997.
J.-H. Han, S. T. Jung, M.-K. Oh (2021) “Improved yield of recombinant protein via flagella regulator deletion in Escherichia coli”, Frontieres in Microbiology, 12, 655072.
S. Ko, M. Jo, S. T. Jung* (2021) “Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering”, BioDrugs, 1-11.
P. Jebamani, S. Sokalingam, D. K. Sriramulu, S. T. Jung, S.-G. Lee (2020) “Assessment of computational modeling of Fc-Fc receptor binding through protein-protein docking tool.”, Biotechnology and Bioprocess Engineering 25, 734-741.
M.-S. Ju, S. T. Jung* (2020) “Antigen design for successful isolation of highly challenging therapeutic anti-GPCR antibodies.”, International Journal of Molecular Sciences, 21, 8240.
M. Jo, S. Ko, B. Hwang, S. W. Min, J. Y. Ha, J. C. Lee, S. E. Jang, S. T. Jung (2020) “Engineered Human FcγRIIa Fusion: A Novel Strategy to Extend Serum Half-Life of Therapeutic Proteins.”, Biotechnology and Bioengineering, 117(8):2351-2361. featured on the cover page of the issue, https://doi.org/10.1002/bit.27374.
S. Ko, H. Jeon, S. Yoon, M. Kyung, H. Yun, J. H. Na, S. T. Jung (2020) “Discovery of Novel Pseudomonas putida Flavin-Binding Fluorescent Protein Variants with Significantly Improved Quantum Yield.”, Journal of Agricultural and Food Chemistry, 68:21, 5873-5879.
T. H. Kang, S. T. Jung* (2020) “Reprogramming the constant region of immunoglobulin G subclasses for enhanced therapeutic potency against cancer”, Biomolecules, 10(3), E382.
J. Lee, B. S. Der, C. S. Karamitros, W. Li, N. M. Marshall, O. I. Lungu, A. E. Miklos, J. Xu, T. H. Kang, C.-H. Lee, B. Tan, R. A. Hughes, S. T. Jung, G. C. Ippolito, J. J. Gray, Y. Zhang, B. Kuhlman, G. Georgiou, A. D. Ellington (2020) “Computer-based Engineering of Thermostabilized Antibody Fragments”, AIChe Journal, 66(3), e16864.
T. H. Kang, S. T. Jung* (2019) “Boosting therapeutic potency of antibodies by taming Fc domain functions”, Experimental and Molecular Medicine, 51(11), 138.
S. H. Ko, B. Hwang, J.-H. Na, J. Lee, S. T. Jung* (2019) “Engineered Arabidopsis blue light receptor LOV domain variants with improved quantum yield, brightness, and thermostability”, Journal of Agricultural and Food Chemistry, 67:43, 12037-12043.
H. W. Yoon, M. Jo, S. Ko, H. S. Kwon, C. S. Lim, B. J. Ko, S. T. Jung* (2019) “Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies”, Molecular Immunology, 114, 62-71.
B. S. Lee, Y. Lee, J. Park, B. S. Jeong, M. Jo, S. T. Jung, T. H. Yoo (2019) “Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A”, Journal of Biological Engineering, 13, 56.
J. H. Jung, S.-G. Han, M.-S. Ju, S. T. Jung, Y. G. Yu (2019) "Isolation of Single Chain Antibodies Specific to Lysophosphatidic Acid Receptor 1 (LPA1) from a M13 Phage Display Library Using Purified LPA1 Stabilized in Nanodiscs", Bulletin of Korean Chemical Society, 40:7, 680-685.
M. Jo, H. S. Kwon, K.-H. Lee, J. C. Lee, S. T. Jung* (2018) “Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance”, mAbs, 2:10, 278-289.
M. Jo, B. Hwang, H. W. Yoon, S. T. Jung* (2018). "E. coli inner membrane display system for high-throughput screening of dimeric proteins" Biotechnology and bioengineering, featured on the cover page of the issue.
H. Son, S.-I. Baek, M.-S. Ju, S.-G. Han, S. T. Jung, Y. G. Yu (2018). "Development of single-chain antibodies specific to lysophosphatidic acid receptor 2.", Bulletin of Korean Chemical Society, 39:4, 489-494.
M.-S. Ju, S.-W. Min, S. Lee, H. S. Kwon, J. C. Park, J. C. Lee*, S. T. Jung* (2017). "A synthetic library for rapid isolation of humanized single-domain antibodies." Biotechnology and Bioprocess Engineering. 22. 239-247.
S.-G. Han, S. Ko, W.-K. Lee, S. T. Jung*, Y. G. Yu* (2017) “Determination of the endothelin-1 recognition sites of endothelin receptor type A by the directed-degeneration method”, Scientific Reports, 7, 7677.
S. Chauhan, C. Y. Hou, S. T. Jung, T. J. Kang* (2017) “Detection and Detection and purification of backbone-cyclized proteins using a bacterially expressed anti-myc-tag single chain antibody, Analytical Biochemistry, 532, 38-44.
H. I. Park, H. W. Yoon, S. T. Jung*, (2016) “The highly evolvable antibody Fc domain", Trends in Biotechnology, 34:11, 895-908.
M. Jo, S. T. Jung* (2016) “Engineering therapeutic antibodies targeting G-protein-coupled receptors”, Experimental and Molecular Medicine, 48, e207.
M.-S. Ju, J.-H. Na, Y. G. Yu, J.-Y. Kim, C. Jeong, S. T. Jung* (2015) “Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding”, Molecular Immunology, 67, 350-356.
S. H. Ko, S. T. Jung* (2015) “Engineering antibodies for dual specificity and enhanced potency”, Biotechnology and Bioprocess Engineering, 20, 201-210.
S. T. Jung*, T. H. Kang, D. I. Kim (2014) “Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding”, Biotechnology and Bioprocess Engineering, 19, 780-789.
M.-S. Ju, S. T. Jung*, (2014) “Aglycosylated full-length IgG antibodies steps toward next-generation immunotherapeutics, Current Opinion in Biotechnology, 30, 128-139.
Laserson, U., F. Vigneault, D. Gadala-Maria, G. Yaari, M. Uduman, J. A. Vander Heiden, W. Kelton, S. T. Jung, Y. Liu, J. Laserson, R. Chari, J.-H. Lee, I. Bachelet, B. Hickey, E. Lieberman-Aiden, B. Hanczaruk, B. B. Simen, M. Egholm, D. Koller, G. Georgiou, S. H. Kleinstein, and G. M. Church, (2014) ” High-resolution antibody dynamics of vaccine-induced immune responses”, Proceedings of the National Academy of Sciences USA (PNAS), 111:13, 4928-4933
S. T. Jung*, (2013) “Tailoring immunoglobulin Fc for highly potent and serum-stable therapeutic antibodies”, Biotechnology and Bioprocess Engineering, 18:4, 623-636.
J.-H. Na, M.-S. Joo, W.-K. Lee, H. Shim, S.-H. Lim, S. T. Jung, Y. G. Yu, (2013) ”Development of a single chain antibody using a phage display cloning method for the detection of 2,4-dinitrotoluene”, Bulletin of Korean Chemical Society, 34:2, 460-464.
H. H. Lee, S. T. Jung, (2013) ”Overexpression, crystallization, and preliminary X-ray crystallographic analysis of β-N-acetylglucosaminidase from Thermotoga maritime by the Tm0809 gene”, Acta Crystallographica Section F, 69:Pt2, 115-117.
Y. Wine, D. R. Boutz, J. J. Lavinder, A. E. Miklos, R. A. Hughes, K. H. Hoi, S. T. Jung, A. P. Horton, A. D. Ellington, E. M. Marcotte, G. Georgiou, (2013) ”Molecular deconvolution of the polyclonal antibody serum response”, Proceedings of the National Academy of Sciences USA (PNAS), 110:8, 2993-2998.
S. T. Jung, W. Kelton, T. H. Kang, D. T. Ng, J. T. Andersen, I. Sandlie, C. A. Sarkar, G. Georgiou, (2013) ”Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity”, ACS Chemical Biology, 8:2, 368-375.
H. K. Yoon, S. T. Jung, J. Kim, T. H. Yoo, (2012) “Recent Development of Highly Sensitive Protease Assay Methods: Signal Amplification through Enzyme Cascades”, Biotechnology and Bioprocess Engineering, 17, 1113-1119.
S. T. Jung*, (2012) “Engineering Aglycosylated Antibodies for Therapeutic Effector Functions and Production in Bacteria”, BT News, 19:2, 70-73.
E. M. Brustad, V. S. Lelyveld, C. D. Snow, N. Crook, S. T. Jung, F. M. Martinez, T. J. Scholl, A. Jasanoff, F. H. Arnold, (2012) “Structure-guided directed evolution of highly selectively P450-based magnetic resonance imaging sensors for dopamine and serotonin”, Journal of Molecular Biology, 422:2, 245-262.
M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, G. Georgiou, (2012) ”Revisiting the role of glycosylation in the structure of human IgG Fc”, ACS Chemical Biology, 7:9, 1596-1602.
S. T. Jung, T. H. Kang, W. Kelton, G. Georgiou, (2011) “Bypassing glycosylation: Engineering aglycosylated full length IgG antibodies for human therapy, Current Opinion in Biotechnology, 22:6, 858-867.
S. T. Jung, R. Lauchli, F. H. Arnold, (2011), “Cytochrome P450: taming a wild type enzyme”, Current Opinion in Biotechnology, 22:6, 809-817.
J. Qiu, S. T. Jung, G. Georgiou, H. Hang, (2010), “Enrichment of Escherichia coli spheroplasts displaying scFv antibodies specific for antigens expressed on the human cell surface”, Applied Microbiology and Biotechnology, 88:6, 1385-1391.
S. T. Jung, T. H. Kang, G. Georgiou (2010), “Efficient expression and purification of human aglycosylated Fcγ receptors in Escherichia coli”, Biotechnology and Bioengineering, 197:1, 21-30.
S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, G. Georgiou (2010), “Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells”, Proceedings of the National Academy of Sciences USA (PNAS), 107:2, 604-609.
Highlighted in Nature Biotechnology (2010), 28:1, 45, “Research Highlights”, “Receptor-selective aglycosylated Abs”,
Highlighted in Nature SciBX (Science Business eXchange) (2010), 3:3, Jan 21, 2010 issue, “Cover Story”, “mAbs that live long and prosper”,
http://www.nature.com/scibx/journal/v3/n3/full/scibx.2010.73.html
S. T. Jung, K. J. Jeong, B.L. Iverson, G. Georgiou (2007), “Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens”, Biotechnology and Bioengineering, 98:1, 39-47.
Highlighted “Spotlight” Biotechnology and Bioengineering (2007), 98:1, “Toward the Isolation of Antibodies to Surface Biomarkes”.
M. S. Kim, S. S. Kim, S. T. Jung, J. Y. Park, H. W. Yoo, J. Ko, K. Csizar, S. Y. Choi, and Y. Kim (2003), “Expression and purification of enzymatically active form of the human lysyl oxidase-like protein 4”, Journal of Biological Chemistry, 278:52, 52071-52074.
S. T. Jung, M. S. Kim, J. Y. Seo, H. C. Kim, and Y. Kim (2003), “Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies”, Protein Expression and Purification, 31, 240-246.
S. H. Kang, S. T. Jung, T. J. Kang, R. G. Kim, S. H. Suh, J. H. Woo, E. L. Lee, and C. Y. Choi (1999), “An efficient translational termination of human erythropoietin in Escherichia coli by altering the base following the stop codon”, Biotechnology and Techniques, 13, 761-764.
T. J. Kang, S. H. Kang, S. T. Jung, E. L. Lee, and C. Y. Choi (1999), “A simple regression method for determining the quantity of translated protein in a cell free protein synthesis system”, Journal of Bioscience and Bioengineering, 88:3, 345-347.